Key Takeaways U.S. equities sank at midday Thursday, April 25, 2024 as a report showed U.S. economic growth was lower than ...

The new Merck Biotechnology Learning Center is designed to foster that kind of STEM workforce success. Sanat Chattopadhyay, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck’s stocks saw a bump on Thursday after the pharmaceutical giant reported a boom in first-quarter sales of its blockbuster cancer drug Keytruda, according to the firm’s latest earnings ...

Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant ...

The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who ...

Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street ...

RAHWAY, N.J. — RAHWAY, N.J. — Merck & Co. (MRK) on Thursday reported first-quarter earnings of $4.76 billion. On a per-share basis, the Rahway, New Jersey-based company said it had profit of ...

(Adds details from investor call in paragraphs 7 and 8, updates shares) By Patrick Wingrove and Leroy Leo April 25 (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecasts ...

Arne Dedert / picture alliance via Getty Images Merck beat earnings and revenue estimates on strong sales of its Keytruda cancer medicine and Gardasil HPV vaccine. The pharmaceutical giant ...

Shares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its blockbuster cancer drug Keytruda fueled a higher-than-expected increase in quarterly sales and earnings.